Charles Riv Labs Intl Inc SEC Filings

Charles River Laboratories (CRL) Form 144 discloses a proposed sale of 22,500 shares of common stock through Merrill Lynch on or about 08/18/2025 with an aggregate market value of $3,420,000. The notice identifies the seller as Richard Wallman and shows prior acquisitions by the seller including RSU vesting from 2017–2019 and multiple open-market purchases in June–July 2025 totaling 15,000 shares. The filing also reports recent sales by the same person in the past three months: 4,000 shares on 06/23/2025 for $550,000 and 8,500 shares on 07/21/2025 for $1,275,000. The filer certifies no undisclosed material adverse information.

Form 144 notice for Charles River Laboratories (CRL) discloses a proposed sale of 800 shares of common stock through UBS Financial Services (Weehawken, NJ) with an aggregate market value of $125,600. The shares represent part of outstanding common stock of 49,120,000 and an approximate sale date of 08/18/2025 on the NYSE. The filing shows the shares were acquired as Performance Stock Units on 01/27/2023 from Charles River Laboratories and that payment at sale is expected in cash. The filer previously sold 400 shares on 08/07/2025 for $59,991. The notice includes the customary attestation that the seller is unaware of undisclosed material adverse information.

Nomura Holdings, Inc. reports beneficial ownership of 2,681,669 shares of Charles River Laboratories common stock, representing 5.4% of the outstanding class. The total includes 473,087 shares held by Nomura Global Financial Products, Inc. (NGFP), 1,096,182 shares held by Nomura Securities International, Inc. (NSI), and call options exercisable within 60 days covering 1,112,400 shares (1,100,000 by NGFP and 12,400 by NSI). The percent is calculated using 49,209,000 shares outstanding as of June 28, 2025, per the issuer's quarterly report. The filing states these holdings were acquired and are held in the ordinary course of business.

Charles River Laboratories EVP Joseph W. LaPlume reported a sale of 400 shares of common stock on 08/07/2025 at $150.04 per share. After the transaction he directly owned 24,916 shares. The filing is a routine Form 4 disclosure recording an officer's change in beneficial ownership and shows no derivative transactions.

Form 144 filing for Charles River Laboratories International, Inc. (CRL) discloses a planned sale of 4,000 common shares through Merrill Lynch, valued at $550,000. The filer expects the transaction to occur on or about 06/23/2025. Total shares outstanding are reported at 49,115,712, so the proposed sale represents roughly 0.008% of the public float. The shares being sold were acquired on 06/02/2025 via an open-market purchase and will be settled for cash. No prior sales were reported in the past three months, and the form contains no remarks indicating special circumstances. The identity of the filer, their relationship to CRL, and any 10b5-1 plan details were not provided.

The filing is a routine notice of intent required under Rule 144 and does not, by itself, finalize the sale. Given the relatively small size versus market capitalization and the absence of additional context, the disclosure is likely to have limited market impact.